BET inhibitors synergize with sunitinib in melanoma through GDF15 suppression

• Published in: Experimental & molecular medicine Vol. 55; no. 2; pp. 364 - 376
• Main Authors: Zeng, Furong, Li, Yayun, Meng, Yu, Sun, Huiyan, He, Yi, Yin, Mingzhu, Chen, Xiang, Deng, Guangtong
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.02.2023; Springer Nature B.V; Nature Publishing Group; 생화학분자생물학회
• Subjects: 13/109; 13/2; 13/31; 13/51; 13/95; 14/1; 38/47; 38/91; 631/67/1813/1634; 64; 64/60; 692/308/575; 82; 82/80; Antitumor activity; Antitumor agents; Apoptosis; Biomedical and Life Sciences; Biomedicine; Cancer; Cancer therapies; Cell cycle; Cell Cycle Proteins; Cell death; Cell Line, Tumor; Cell Proliferation; FDA approval; Growth Differentiation Factor 15 - genetics; Growth Differentiation Factor 15 - pharmacology; Humans; Inhibitor drugs; Kinases; Medical Biochemistry; Melanoma; Melanoma - drug therapy; Molecular Medicine; Nuclear Proteins - metabolism; Proteins; Stat3 protein; Stem Cells; Sunitinib - pharmacology; Synergism; Targeted cancer therapy; Transcription Factors - metabolism; Xenograft Model Antitumor Assays; Xenografts; 생화학

Targeting bromodomain and extra-terminal domain (BET) proteins has shown a promising therapeutic effect on melanoma. The development of strategies to better kill melanoma cells with BET inhibitor treatment may provide new clinical applications. Here, we used a drug synergy screening approach to comb...